Cell death in the superficial dorsal horn in a model of neuropathic pain.
The aims of this study were to investigate the occurrence of apoptotic cell death in the dorsal horn of the adult rat spinal cord following chronic constriction injury (CCI) to the sciatic nerve and to correlate this with behavioural responses. Six groups of six rats were used as follows: 1) CCI, 2) CCI, 3) MK801 + CCI, 4) axotomy, 5) sham, and 6) naive. Group 1 animals were behaviourally tested for thermal hyperalgesia 8 days following surgery and sacrificed and the spinal cords removed and frozen. The rest of the groups underwent the same procedure 14 days following surgery. The lumbar region of the spinal cord was cryosectioned and the incidence of apoptotic cells investigated using the TUNEL technique plus Hoechst double labelling. By 8 days post-CCI, hyperalgesia had developed in the ipsilateral paw, which was still present 14 days after the injury compared to the contralateral paw and naive and sham animals. Preemptive MK-801 prevented the onset of hyperalgesia. Significant numbers of apoptotic cells were present in the ipsilateral dorsal horn of the spinal cord 8 and 14 days following CCI compared to the contralateral side and to naive and sham animals. Preemptive treatment with MK-801 reduced the extent of apoptosis resulting from CCI to the level seen in control animals. This study demonstrates that cells undergo apoptosis as a result of CCI simultaneous with the occurrence of hyperalgesia. Furthermore, MK-801 prevents the onset of hyperalgesia and reduces the extent of apoptotic cell death, suggesting, perhaps, that apoptosis contributes to the initiation/maintenance of hyperalgesia.
Whiteside
G T
GT
University Department of Anaesthesia, University of Cambridge Clinical School, Addenbrookes Hospital, Cambridge, United Kingdom. gtw20@medschl.cam.ac.uk
Munglani
R
R
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002422:Causalgia / Q000188:drug therapy / Q000473:pathology*; D003250:Constriction; D016291:Dizocilpine Maleate / Q000494:pharmacology / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005727:Ganglia, Spinal / Q000187:drug effects / Q000473:pathology*; D006358:Hot Temperature; D006930:Hyperalgesia / Q000188:drug therapy / Q000473:pathology* / Q000517:prevention & control; D020287:In Situ Nick-End Labeling; D008297:Male; D008959:Models, Neurological; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors; D010243:Paralysis / Q000209:etiology; D020671:Posterior Horn Cells / Q000187:drug effects / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time; D012584:Sciatic Nerve / Q000293:injuries
D018691:Excitatory Amino Acid Antagonists; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate